Arcellx Inc declines amid market weakness
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 05 Dec 25
Arcellx Inc's stock fell by 6.65%, crossing down the 5-day SMA.
The Nasdaq-100 and S&P 500 both experienced slight declines, contributing to a negative market sentiment.
This downward movement may indicate investor caution, reflecting broader market trends.
ACLX
$0.0000%Past 6 months
Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
No Data
Powered By
Intellectia
Analyst Views on ACLX
Wall Street analysts forecast ACLX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ACLX is 114.71 USD with a low forecast of 88.00 USD and a high forecast of 134.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
17 Analyst Rating
15 Buy
2 Hold
0 Sell
Strong Buy
Current: 72.940
Low
88.00
Averages
114.71
High
134.00
Current: 72.940
Low
88.00
Averages
114.71
High
134.00
Citi
Buy
maintain
$110
2025-11-24
Reason
Citi
Price Target
$110
2025-11-24
maintain
Buy
Reason
Citi believes today's weakness in Arcellx is "an overreaction to the highly preliminary" Phase 1 inMMyCAR data for Kelonia Therapeutics' KLN-1010. While the achievement of MRD-negativity is a positive early signal, the study featured just three patients and a maximum of three months' follow-up, "leaving critical questions about response durability entirely unanswered," according to the firm, which would be buyers on the weakness. Citi maintains a Buy rating and $110 price target on Arcellx shares.
Wolfe Research
Peer Perform
initiated
2025-11-17
Reason
Wolfe Research
Price Target
2025-11-17
initiated
Peer Perform
Reason
Wolfe Research initiated coverage of Arcellx with a Peer Perform rating and no price target. The firm's analyst of the FDA's FAERS data suggests Carvytki's neurotoxicity is decreasing, but the analyst says its "early to draw any conclusions."
Canaccord
John Newman
Buy
maintain
$121 -> $130
2025-11-03
Reason
Canaccord
John Newman
Price Target
$121 -> $130
2025-11-03
maintain
Buy
Reason
Canaccord analyst John Newman raised the firm's price target on Arcellx to $130 from $121 and keeps a Buy rating on the shares. The firm conducted a detailed analysis of factors limiting Legend / JnJ's CARVYKTI CART launchin Multiple Myeloma, which all suggest favorable launch conditions for Arcellx in 2026. They said based on their analysis of US CARVYKTI revenues, the first four quarters of the CARVYKTI revenue could have been about 2x higher, accounting for issues with Out Of Specification (OOS) product, slow manufacturing time, and infrastructure limitations.
Stifel
Stephen Willey
resume
$129
2025-10-16
Reason
Stifel
Stephen Willey
Price Target
$129
2025-10-16
resume
Reason
Stifel analyst Stephen Willey resumed coverage of Arcellx with a Buy rating and $129 price target. The firm believes anito-cel is "poised to emerge" as a best-in-class BCMA-targeting CAR T therapy for multiple myeloma and anticipates a year-end 2025 BLA submission of iMMagine-1 data to serve as the basis of an approval and launch in the second half of 2026. From there, it expects early-FY27 iMMagine-3 mPFS data serving as the basis of label expansion into second-line and later patients, the analyst tells investors.
See All Ratings
About ACLX
Arcellx Inc. is a clinical-stage biotechnology company reimagining cell therapy by engineering immunotherapies for patients with cancer and other incurable diseases. Its lead program is a BCMA-targeting ddCAR product candidate called anitocabtagene autoleucel, which is being evaluated in its pivotal Phase II iMMagine-1 and the Phase III iMMagine-3 trials in patients with relapsed or refractory multiple myeloma (rrMM). Anitocabtagene is the first BCMA-directed CAR T-cell therapy to be investigated in multiple myeloma that utilizes its novel and compact binder known as the D-Domain. The small, stable D-Domain binder enables high CAR expression without tonic signaling and is designed to quickly release from the BCMA target. It is also developing two clinical-stage ARC-SparX programs in Phase I trials: ACLX-001, which targets BCMA in rrMM, and ACLX-002, which targets CD123 in relapsed or refractory acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS).
About the author
Preview
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Sigh Up to Get Intellectia Insights
How did the company's recent strategic decisions impact its latest financial performance?
Can you explain the factors behind the recent changes in the company's stock price?
What are the expected impacts of current market trends on the company's future growth?
Based on the latest earnings report, what are the company's forecasted revenues for the next quarter?